Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2008
12/18/2008US20080312253 Pharmaceutical compositions containing pyrazole derivatives for treating as serotonin antagonist
12/18/2008US20080312246 Substituted Piperazines as Metabotropic Glutamate Receptor Antagonists
12/18/2008US20080312240 Bicyclic Piperazines as Metabotropic Glutatmate Receptor Antagonists
12/18/2008US20080312237 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
12/18/2008US20080312235 Pyridine Derivatives
12/18/2008US20080312234 Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
12/18/2008US20080312231 N-{2-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-2-oxo-ethoxy]-ethyl}-N-ethyl-4-methoxy-2,3,6-trimethyl-phenylsulfonamide; condensing the N-carboxyalkyl phenylsulfonamide with the substituted piperidine; bradykinin receptor antagonists; analgesics; antidiabetics; angiogenesis inhibitors; rheumatic diseases
12/18/2008US20080312230 Organic Compounds
12/18/2008US20080312229 Organic Compounds
12/18/2008US20080312227 Substituted Pyrido(2,3-D) Pyrimidine Derivatives Useful as Medicines for the Treatment of Autoimmune Disorders
12/18/2008US20080312226 Amide Compound
12/18/2008US20080312224 Oxaphenanthrene Derivatives
12/18/2008US20080312222 4-Benzyledene-Piperidin Derivatives
12/18/2008US20080312214 Treating non-insulin dependent diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome; 6-[(1-cycloheptyl-4,4-dimethyl-5-oxopyrrolidin-3-yl)methoxy]nicotinonitrile for example
12/18/2008US20080312199 Treatments of therapy resistant diseases and drug combinations for treating the same
12/18/2008US20080312187 Phosphoinositide modulation for the treatment of alzheimer's disease
12/18/2008US20080312166 Reversal core pharmaceutical system and method
12/18/2008US20080312165 Process for obtaining pure monosialoganglioside GM1 for medical use
12/18/2008US20080312158 Semaphorin Gene Family
12/18/2008US20080311622 Activatable recombinant neurotoxins
12/18/2008US20080311228 Pharmaceutical composition for protecting neurons comprising extract of lithospermum erythrothizon sieb. et. zucc or acetylshikonin isolated therefrom as an effective ingredient
12/18/2008US20080311208 Pharmaceutical Formulations Useful in the Treatment of Insomnia
12/18/2008US20080311200 Controlled Slow Release Formulation of Thiamine and Use Thereof in the Treatment of Pathologies Connected to Defective Process of Learning and Memorization
12/18/2008US20080311199 Tamper-resistant oral opioid agonist formulations
12/18/2008US20080311198 Tamper-resistant oral opioid agonist formulations
12/18/2008US20080311197 Process for the production of an abuse-proofed dosage form
12/18/2008US20080311193 Sustained Release Formulation of Alprazolam
12/18/2008US20080311187 Crush resistan delayed-release dosage form
12/18/2008US20080311179 for treating disease or condition chosen from Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, sleep, eating disorders
12/18/2008US20080311171 Implantable polymeric device for sustained release of dopamine agonist
12/18/2008US20080311167 Topical Composition for Treating Pain
12/18/2008US20080311156 Vaccines
12/18/2008US20080311132 Human Complement C3 Derivates with Cobra Venom Factor-Like Function
12/18/2008US20080311113 Method for treating adamts-5-associated disease
12/18/2008US20080311107 Novel Gene Disruptions, Compositions and Methods Relating Thereto
12/18/2008US20080311091 Engineered Dopamine Neurons and Uses Thereof
12/18/2008US20080311037 Compounds which bind PSMA and uses thereof
12/18/2008DE102007005045B4 Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Phenothiazine derivatives, processes for their preparation and their use as medicaments
12/18/2008CA2727528A1 Heme-oxygenase inhibitors and use of the same in the treatment of cancer and diseases of the central nervous system
12/18/2008CA2690789A1 4-phenylpiperazine derivatives with functionalized linkers as dopamine d3 receptor selective ligands and methods of use
12/18/2008CA2690468A1 New compounds 892
12/18/2008CA2690455A1 [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases
12/18/2008CA2690299A1 Piperazine and [1,4] diazepan derivatives as nk antagonists
12/18/2008CA2690080A1 Urotensin ii receptor antagonists
12/18/2008CA2689948A1 Gamma secretase modulators
12/18/2008CA2689930A1 Gamma secretase modulators
12/18/2008CA2689549A1 Igf for the treatment of rett syndrome and synaptic disorders
12/18/2008CA2688208A1 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators
12/18/2008CA2687979A1 Sustained delivery formulations of risperidone compounds
12/18/2008CA2687721A1 Crystalline forms of (r)-1-{2-[4'-(3-methoxy-propane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
12/17/2008EP2003134A2 Hydromorphinone and hydrocodeinone compositions and methods for their synthesis
12/17/2008EP2003131A1 Aminopyrrolidine compound
12/17/2008EP2002863A1 [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases
12/17/2008EP2002837A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
12/17/2008EP2002832A2 Composition containing lignan compound
12/17/2008EP2002827A2 Methods and compositions for control of bone formation via modulation of sympathetic tone
12/17/2008EP2002826A1 Titratable dosage transdermal delivery system
12/17/2008EP2002005A1 Identification of crmp4 as a convergent regulator of axon outgrowth inhibition
12/17/2008EP2001891A1 Buprenorphine derivatives and uses thereof
12/17/2008EP2001872A1 Benzofuran compounds as ep1 receptor antagonists
12/17/2008EP2001865A1 Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands
12/17/2008EP2001864A1 Heterocyclic organic compounds for the treatment of in particular melanoma
12/17/2008EP2001863A1 2-(cyclic amino)-pyrimidone derivatives as tpk1 inhibitors
12/17/2008EP2001856A1 Crystalline forms of n- {2-tert -butyl -1- [ (4,4- dif luorocyclohexyl) methyl]-lh-benzimidazol-5- yl}ethanesulfonamide salts
12/17/2008EP2001851A2 Amide derivatives and their application for the treament of g protein related diseases
12/17/2008EP2001849A1 Pyridine and pyrimidine derivatives as mglur2 antagonists
12/17/2008EP2001848A1 Piperidines and related compounds for the treatment of dementia
12/17/2008EP2001831A2 Compounds which inhibit the glycine transporter and uses thereof
12/17/2008EP2001556A1 Thioninium compounds and their use
12/17/2008EP2001505A2 Cathepsin propeptide and uses thereof
12/17/2008EP2001495A2 Methods for regulating neurotransmitter systems by inducing counteradaptations
12/17/2008EP2001467A2 Spirocyclic heterocyclic derivatives and methods of their use
12/17/2008EP2001463A1 A pharmaceutical composition useful as acetyl cholinesterase inhibitors
12/17/2008EP2001456A2 Use of kappa opioid receptor antagonist-containing compositions for the treatment of dissociative disorders
12/17/2008EP2001293A2 Use of ketogenic compounds for treatment of age-associated memory impairment
12/17/2008EP1919883B1 N-oxides as prodrugs of piperazine&piperidine derivatives
12/17/2008EP1753736B1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
12/17/2008EP1703896B1 Pharmaceutical compositions comprising midazolam in a high concentration
12/17/2008EP1610796A4 High potency dopaminergic treatment of neurological impairment associated with brain injury
12/17/2008EP1536778B1 Proteins binding to cross-beta structure comprising amyloid and methods for modulation of the cross-beta structure, its formation and its associated toxicity
12/17/2008EP1503759B1 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof
12/17/2008EP1425001B1 Phenethanolamine derivatives for treatment of respiratory diseases
12/17/2008EP1423106B1 Arylsulfonyl derivatives with 5-ht 6 receptor affinity
12/17/2008EP1369119B1 Il-12 expression controlling agents
12/17/2008EP1330244B1 Compositions comprising modafinil compounds
12/17/2008EP1230214B1 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof
12/17/2008EP1077943B1 Heterocyclic inhibitors of p38
12/17/2008EP0791067B1 Protein kinase npk-110
12/17/2008CN101326179A New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease
12/17/2008CN101326171A Novel dual peptidase inhibitors as prodrugs for the therapy of inflammatory and other disorders
12/17/2008CN101326163A Prolinamide derivatives as sodium channel modulators
12/17/2008CN101326162A Quaternary alpha-aminocarboxamide derivatives as modulators of voltage-gated sodium channels
12/17/2008CN101325972A A beta 1-42 specific monoclonal antibodies with therapeutic properties
12/17/2008CN101325954A Quinazolinone derivatives as vanilloid antagonists
12/17/2008CN101323860A Novel biological method for detoxification
12/17/2008CN101323641A Anti-opioid peptide, antagonistic peptide thereof and use thereof
12/17/2008CN101322833A Sedative and brain-invigorating oral liquid with improved clarity and stability and preparation thereof
12/17/2008CN101322830A Medicament for treating postpartum depression and preparation method thereof
12/17/2008CN101322824A Oral liquid for refreshing oneself, promoting digestion and enriching blood
12/17/2008CN101322806A Chinese medicine for treating epilepsy and hyperkinetic symptom of children
1 ... 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 ... 1833